Published 9 hours ago • loading... • Updated 10 hours agoShow Less IconPhathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Target Lowered at Barclays Summary by MarketBeatBarclays lowered their target price on Phathom Pharmaceuticals from $14.00 to $10.00 and set an "overweight" rating for the company in a report on Wednesday.Share menu1 Articles1 ArticlesAllLeftCenter1RightSearch IconSort IconMarketBeatCenterFactualityOwnershipPhathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Target Lowered at BarclaysBarclays lowered their target price on Phathom Pharmaceuticals from $14.00 to $10.00 and set an "overweight" rating for the company in a report on Wednesday.10 hours ago·Sioux Falls, United StatesRead Full ArticleThink freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribeBlindspot Title And LogoStories disproportionately reported by the Left or the RightSee More BlindspotsCoverage DetailsTotal News Sources1Leaning Left0Leaning Right0Center1Last Updated9 hours agoBias Distribution100% CenterBias Distribution Too Big Arrow IconToo Big Arrow IconCaret Up Icon100% of the sources are Center100% CenterC 100%Factuality Info IconTo view factuality data please Upgrade to PremiumOwnership Info IconTo view ownership data please Upgrade to VantageMarketBeat broke the news in Sioux Falls, United States 10 hours ago on Wednesday, November 18, 2026.Too Big Arrow IconCaret Down IconSources are mostly out of (0)Similar News TopicsNvidia Plus IconStock Markets Plus IconSouth San Francisco Plus IconShow AllBlindspot Title And LogoStories disproportionately reported by the Left or the RightSee More BlindspotsSimilar News TopicsNvidia Plus IconStock Markets Plus IconSouth San Francisco Plus IconShow All